Skip to main content
Equibles
VXRT logo

VXRT

Vaxart, Inc.
$0.55 +0.00 (+0.00%) At close · Jul 8
Market Cap
$133.09M
Shares
241,973,011

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.55 Open$0.54 Day$0.52–0.55 52W$0.26–0.84 Avg vol 30d333K Short int2.6M · 1.1% float · 4.2d Short vol30% Last earningsMay 7, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 7
Equibles Rating blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Neutral Momentum Neutral Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 16.9 · calm Equity put/call 0.86
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +1%
above
Price vs 50-day avg −13%
below
RSI (14) 43
neutral
MACD trend Positive
52-week position 50%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return −8%
trailing
6-month return +4%
trailing
YTD return +57%
this year
Relative strength −4%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +2 funds added
Insider flow Accumulating
Net +$6.5K over 90 days · 0% sells
Short interest Falling
1.09% of float · ▼ -1.1% MoM · 4.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
5 holders — near 3-yr low, contrarian setup
Squeeze score 39
low risk · 0–100
Fundamentals
Excellent
Revenue growth +727%
Y/Y
EPS growth +121%
Y/Y
Free cash flow $7.6M
Balance sheet $17.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 96%
annualized · 1-yr
Max drawdown −36%
past year
ATR 9.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next
Next earnings call
Aug 7, 2026 Est · unconfirmed · in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 7, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 4 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +1% Bullish
      Price vs 50-day avg
      −13% Bearish
      RSI (14)
      43 Neutral
      MACD trend
      Positive Bullish
      52-week position
      50% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $1 › 200d $1 — 50d above 200d
      Institutional flow Flat
      0% holders QoQ · +2 funds added
      Insider flow Accumulating
      Net +$6.5K over 90 days · 0% sells
      Short interest Falling
      1.09% of float · ▼ -1.1% MoM · 4.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      5 holders — near 3-yr low, contrarian setup
      Price context
      position in its 52-week range
      52-wk low $0 Now $1 · 50% 52-wk high $1
      vs 200-day avg +1% vs 50-day avg -13%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Cumulative cash payments associated with the BARDA contract $218.9M as of March 31, 2026 —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      VXRT
      Vaxart, Inc.
      this stock
      		$133.09M +57.1% +726.7% — 1.1%
      ONC
      BeOne Medicines Ltd.
      		 $446.53B +1.7% +22179.2% 908.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $126.50B +9.9% +46.2% 29.6 1.8%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $69.50B -14.0% +20.8% 16.5 3.2%
      ARGX
      Argenx SE
      		 $57.20B +8.8% — — 2.4%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      5
      % held
      0.0%
      Net QoQ
      -6.3K sh
      Top holder
      Heritage Wealth Advisors
      Held Float
      View
      Held by Funds
      Fund positions
      1
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      2.6M
      Days to cover
      4.2d
      Change
      -28.9K sh
      View
      Short Volume
      Short vol %
      30%
      As of
      Jul 8, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      9.2K
      Value
      $5.7K
      As of
      Jun 3, 2026
      View
      Off-Exchange
      Off-exchange %
      100.0%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net buying
      Net (90d)
      +$6.5K
      Buyers / Sellers
      1 / 0
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $237.3M
      Net income (FY)
      $16.3K
      EPS diluted
      $0.07
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 7, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $14.4K
      Shares
      40.0K
      Filed
      Dec 8, 2025
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 7, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      VXRT -9.8% -8.3% +3.8% -9.8% +57.1%
      SPY -0.2% +0.8% +7.4% -0.2% +9.3%
      vs SPY -9.7% -9.2% -3.7% -9.7% +47.8%
      Key facts CIK 72444 CUSIP 92243A200 Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)